The first hepatitis B vaccine was approved in the United States in 1981. This early vaccine was plasma-derived, made from the blood of hepatitis B virus carriers. A safer, genetically engineered recombinant vaccine replaced the plasma-derived version in 1986. The recombinant vaccines are currently used and do not contain blood products, eliminating the risk of transmission through the vaccine itself.